

Science Editor

Na Ma, Company Editor-in-Chief, Editorial Office

Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Paris, Tuesday 26th of May 2020

Dear Madam, Dear Sir,

Please find enclosed the revised manuscript in Word format (file name "Revised manuscript").

Name of journal: World Journal of Clinical Oncology

Manuscript NO.: 53011

Column: Case Report

Title: Case report: Complete Response in Anaplastic-Lymphoma-Kinase-Rearranged Oncocytic Thyroid Cancer

Authors: Victoire de Salins, Gokoulakrichenane Loganadane, Charlotte Joly, Mukedaisi Abulizi, Maya Nourieh, Helene BouSSION, Yazid Belkacemi, Christophe Tournigand and Emmanuelle Kempf

Corresponding author: Christophe Tournigand, MD, PhD, Chief Doctor, Full Professor, Professor, Medical oncology, Hospital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France. christophe.tournigand@aphp.fr

Received Date: 2020-01-18

First decision: 2020-04-12

Science Editor :2020-05-25

We are once again extremely thankful for your trust in our work and read thoroughly through your science editor advices. We modified the paper according to the science editor's comments. We hope that the revised version will fulfill the requirements for final acceptance and publication in the World Journal of Clinical Oncology.

Thank you very much.

Please answer the questions and/or revise the manuscript re-reviewed by #02476743 :

We answered to all the reviewers' comments, making a point-to-point answer (see below).

Overall comments: This case report was discussed the complete response to crizotinib in anaplastic lymphoma kinase–rearranged oncocyctic thyroid cancer. There are several areas where the manuscript needs to be strengthened.

Specific comments:

1.Statement of Ethics: In addition to Institutional Review Board approval, authors should also state that subject have given their written informed consent

Authors' answers : Thank you for your encouragements and thoughtful comments.

- 1) We have obtained informed written consent from the patient for publication of this report and any accompanying images as written in the footnotes. We added this statement at the end of the introduction. We provided the editors with the related document.

2. More discussion regarding the medical policy implications of their findings would be essential for the use of methodology in medical decision making.

Authors' answers :

- 2) We added comments in the limitation subsection about medical implications. « Biology-driven decisions should be enhanced, especially for patients suffering from rare tumors with bad clinical prognosis who could benefit from the screening of oncogenic molecular targets. Further studies are warranted to confirm our findings, with comparison with standard of care treatment. »

3.The authors should add the comments related to selection bias in this study to the perceived limitation subsection.

Authors' answers :

- 3) We have added a subsection and comments on the main limitations of this case report. « Despite this encouraging response, this case report presents some limitations. On this unique case, there is a lack of evidence to generalize and no possibility to establish cause-effect relationship. »

4. Some references should be updated.

Authors' answers :

4) We went through all references, and found a unique update for the "AcSé crizotinib" phase II study, and changed the text accordingly "Second, we followed the "AcSé crizotinib" phase II study, promoted by the French National Cancer Institute, which encouraged secure access to innovative treatments for 235 patients with malignant disease harboring a molecular target such as *ALK*, *MET* or *ROS1*^[25]."

Reference : **Vassal G**, Cozic N, Ferretti G, Taieb S, Houot R, Brugieres L, Aparicio T, Blay JY, Bieche I, Lantuejoul S, Mahier - Ait Oukhatar C, Hoog Labouret N, Moro-Sibilot D. Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSé Program. *J. Clin. Oncol* 2018 ; **36**, 2504–2504 [DOI: 10.1200/JCO.2018.36.15_suppl.2504]

Totally, I would like to congratulate the authors for the enthusiasm invested in this study. However, the manuscript does not reach the level of quality required for publication as original research without major revision in World Journal of Clinical Oncology.

Authors' answers : Thank you very much for your encouragements. We hope that this revised manuscript will reach the level of quality required.

2. Please re-provide the original figure documents. All submitted figures, including the text contained within the figures, must be editable. Please provide the text in your figure(s) in text boxes; For line drawings that were automatically generated with software, please provide the labels/values of the ordinate and abscissa in text boxes; Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

Authors' answers : We added all the figures, and provided texts, graphs and arrows. They can all be reprocessed by the editor and can be found at the end of the manuscript.

3. Please upload the primary version (PDF) of the Informed Consent Form (Surgical operation or other) that has been signed by the patients in the study, prepared in the official language of the authors' country to the system; for example, authors from China should upload the Chinese version of the document, authors from Italy should upload the Italian version of the document, authors from Germany should upload the Deutsch version of the document, and authors from the United States and the United Kingdom should upload the English version of the document, etc.

Authors' answers : We uploaded the primary version of the Informed Consent that has been signed by the patients in the study (black ink) prepared in the official language of our country (French).

Thank you for considering this ultimate review.

Sincerely yours,

Pr. Christophe Tournigand, MD, PhD
Department of Medical Oncology
Henri Mondor & Albert Chenevier Teaching Hospital
51 avenue du Maréchal de Lattre de Tassigny
94010 Créteil, France
christophe.tournigand@aphp.fr